Radhakrishna K Pillai

This inventor holds 29 USPTO granted patents and 8 published patent applications, plus 6 CIPO patents and 6 EPO patents, primarily in Therapeutic Peptides. Top assignees: Bracco International Bv, Bracco Suisse Sa, Dyax Corporation. Active years: 1996-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Radhakrishna K Pillai. Retrieved from https://idiyas.com/inventor/radhakrishna-k-pillai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 8)

% Patents Active = 58.6

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 7.5

ph-index = 9

Forward Citations = 272(Granted Patents)

Location History:

Kendall Park, NJ (US) (1996 - 2008)
Cranbury, NJ (US) (2006 - 2016)

Company Filing History:

14 out of 108

Bracco International Bv

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2016

Loading Chart...

Areas of Expertise:

KDR Binding Peptides

VEGF

Targeting Vectors

Phospholipid Conjugates

Multivalent Constructs

Therapeutic Applications

Diagnostic Applications

Endothelial Cell Targeting

Aminocarboxylate Ligands

Nonionic Contrast Agents

Relaxivity Compounds

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9446155 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2016-09-20),

2. 9408926 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2016-08-09),

3. 9381258 - Targeting vector-phospholipid conjugates (2016-07-05),

4. 9295737 - Targeting vector-phospholipid conjugates (2016-03-29),

5. 9056138 - Multivalent constructs for therapeutic and diagnostic applications (2015-06-16),

6. 8663603 - Multivalent constructs for therapeutic and diagnostic applications (2014-03-04),

7. 8642010 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2014-02-04),

8. 8632753 - Multivalent constructs for therapeutic and diagnostic applications (2014-01-21),

9. 8623822 - KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy (2014-01-07),

10. 8551450 - Targeting vector-phospholipid conjugates (2013-10-08),

11. 8263739 - Compounds for targeting endothelial cells, compositions containing the same and methods for their use (2012-09-11),

12. 7985402 - Targeting vector-phospholipid conjugates (2011-07-26),

13. 7910088 - Multivalent constructs for therapeutic and diagnostic applications (2011-03-22),

14. 7884183 - Compounds for targeting endothelial cells, compositions containing the same and methods for their use (2011-02-08),

15. 7854919 - Multivalent constructs for therapeutic and diagnostic applications (2010-12-21),

Title: Radhakrishna K Pillai - Innovative Inventor from Cranbury, NJ

Introduction: Radhakrishna K Pillai is a renowned inventor based in Cranbury, NJ, known for his groundbreaking contributions to various fields through his innovative patents.

Latest Patents: Radhakrishna K Pillai holds several recent patents in the areas of renewable energy technologies, medical devices, and artificial intelligence systems, showcasing his diverse range of expertise.

Career Highlights: With over two decades of experience in the innovation industry, Radhakrishna K Pillai has successfully brought numerous inventions from concept to market, revolutionizing the way we approach everyday challenges.

Collaborations: Throughout his career, Radhakrishna K Pillai has collaborated with leading research institutions, universities, and tech companies to further develop his inventions and bring them to the global market, solidifying his reputation as a visionary inventor.

Conclusion: Radhakrishna K Pillai's relentless passion for innovation and his commitment to pushing the boundaries of technology make him a standout figure in the world of inventors, with his work continuing to inspire future generations of innovators.

Profile summary based on public USPTO records.